Communiqués Precigen, Inc.

Actions

PGEN

US74017N1054

Produits pharmaceutiques

Temps réel estimé Cboe BZX 19:15:51 09/09/2026			Varia. 5j.	Varia. 1 janv.
6,765 ^USD	-1,53%		-3,35%	+62,08%

31/08	Un initié de Precigen a vendu des actions pour une valeur de 1 376 400 $, selon un récent dépôt auprès de la SEC	MT
25/08	Un dirigeant de Precigen cède pour 375 000 $ d'actions, selon un récent dépôt auprès de la SEC	MT

Communiqués

25/08	Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers	AQ
05/08	Precigen : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
04/08	Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth	PR
21/07	Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4	PR
15/06	Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging	AQ
11/06	Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices	PR
30/05	Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years	PR
27/05	Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States	PR
26/05	Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference	PR
13/05	Precigen Reports First Quarter 2026 Financial Results and Business Updates	PR
07/05	Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13	PR
07/04	Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million	AQ
30/03	Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31	PR
25/03	Precigen Reports Full Year 2025 Financial Results and Business Updates	PR
11/03	Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25	PR
20/01	New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis	PR
12/01	Precigen : January 2026	PU
12/01	Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference	PR
05/01	Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference	PR
13/11	Precigen Reports Third Quarter 2025 Financial Results and Business Updates	PR
06/11	Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13	PR
13/10/25	Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis	PR
03/09/25	Precigen Announces Up to $125 Million Non-Dilutive Financing	PR
25/08/25	Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright	PR
18/08/25	Precigen : PAPZIMEOS Approval Call Precigen August 2025 FINAL	PU